%0 Journal Article
%T 线粒体核糖体蛋白12在肾透明细胞癌中的研究进展<br>Research Progress of MRPL12 in Clear Cell Renal Cell Carcinoma
%A 苏桐
%J Advances in Clinical Medicine
%P 1462-1469
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/ACM.2024.141210
%X 肾细胞癌(renal cell carcinoma, RCC)是起源于肾小管上皮的恶性肿瘤，占肾脏恶性肿瘤的80%~90%，最常见的组织病理类型为透明细胞癌。线粒体核糖体蛋白12 (Mitochondrial ribosomal protein L7/L12, MRPL12)是哺乳动物中鉴定出来的第一种线粒体核糖体蛋白。近年来，线粒体作为潜在的癌症治疗靶点受到了广泛关注。MRPL12作为调节线粒体生物合成及能量代谢的关键蛋白，是线粒体核糖体蛋白中目前报道的唯一可以调控线粒体mtDNA转录和生物合成的蛋白。本研究就MRPL12分子对线粒体的调控作用进行讨论，通过生信分析预测评估MRPL12与肾透明细胞癌的相关性，有助于进一步探究MRPL12在肾透明细胞癌中的分子机制和功能。<br />
Renal cell carcinoma (RCC) is a malignant tumor originating from the epithelium of renal tubules, accounting for 80% to 90% of renal malignancies, and the most common histopathological type is clear cell carcinoma. Mitochondrial ribosomal protein L7/L12 (MRPL12) is the first mitochondrial ribosomal protein identified in mammals. In recent years, mitochondria have received much atten-tion as potential targets for cancer therapy. MRPL12, as a key protein regulating mitochondrial bi-osynthesis and energy metabolism, is the only mitochondrial ribosomal protein reported to regu-late mitochondrial mtDNA transcription and biosynthesis. In this study, we provide an overview on the regulatory role of MRPL12 on mitochondria, and assess the correlation between MRPL12 and renal clear cell carcinoma by biological information analysis, which will help to further explore the molecular mechanism and function of MRPL12 in ccRCC.
%K 线粒体核糖体蛋白，MRPL12，肾透明细胞癌，线粒体生物合成<br>Mitochondrial Ribosomal Protein
%K MRPL12
%K ccRCC
%K Mitochondrial Biosynthesis
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=79996